The whole-exome sequencing test is an in-house developed test that integrates over 1000 clinically significant SN and InDel hotspot mutation sites with internal and public databases. With no more than 100 ng DNA input, the limit of detection (LoD) is 3% for SNV, InDel, and fusion callings.
Product Introduction
Maximizing DNA Mutation Landscape
Based on Burning Rock internal database & public database, integrate common 1000+ clinically significant SN/InDel hotspot mutation sites
Fully Validated
Validation conditions for FFPE / WBC-derived DNA at 500x/150x target sequencing depth:
LoD of SNV & Indels: as low as 3% AF; LoD of Fusions: as low as 6% AF; LoD of CNV: ≥ 3.5CN
Flexible Integration for Expanded Applications
Enables baseline tumor profiling for personalized, tumor-informed MRD detection.
Integrates seamlessly with RNA sequencing for multi-dimensional genomic analysis.
Compatible with methylation sequencing to support comprehensive multi-omics studies.
By submitting this form, or by checking the box above the “Submit” button (if applicable),
you agree that your information will be processed according to Burning Rock’s privacy policy
to provide you with the information and/or general marketing communications (if applicable)
you have requested here. Burning Rock Dx is committed to protecting and respecting your
privacy.
We would like to collect certain personal information about you through cookies and similar technologies
in order to personalize the site for you, improve the performance of the site, and support our marketing
efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your
personal information in accordance with our Privacy Policy, which may include
online targeted and social media advertising in some instances. You can by clicking “Reject All”, you
can reject all cookies except for Strictly Necessary Cookies."
